Colistin monotherapy vs. combination therapy: Evidence from microbiological, animal and clinical studies

Clinical Microbiology and Infection

Volumn 14, Issue 9, 2008, Pages 816-827

  Petrosillo, N ^a   Ioannidou, E ^b   Falagas, M E ^b,c  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acinetobacter baumannii; Bacteraemia; Carbapenem; Escherichia coli; Klebsiella pneumoniae; Multiple drug resistance; Pneumonia; Polymyxins; Pseudomonas aeruginosa; Rifampicin

Indexed keywords

AMIKACIN; AZITHROMYCIN; AZLOCILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BUFORMIN; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; MEROPENEM; MINOCYCLINE; PIPERACILLIN; RIFAMPICIN; SARALASIN; SULBACTAM; SULTAMICILLIN; TACHYPLESIN; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CREATININE CLEARANCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ESCHERICHIA COLI; EVIDENCE BASED MEDICINE; EXPERIMENTAL ANIMAL; HUMAN; KIDNEY FAILURE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; SIDE EFFECT;

ACINETOBACTER BAUMANNII; ANIMALIA; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA; SCOPUS;

EID: 50149096410     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02061.x     Document Type: Review

References (50)

1. Falagas ME, Bliziotis IA. Pandrug-resistant gram-negative bacteria: The dawn of the post-antibiotic era? Int J Antimicrob Agents 2007; 29: 630-636.
2. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-1341.
3. Li J, Nation RL, Turnidge JD et al. Colistin: The re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
4. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 1-25.
5. Evans ME, Feola DJ, Rapp RP. Polymyxin.B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960-967.
6. Livermore DM. The need for new antibiotics. Clin Microbiol Infect 2004; 10 (suppl 4): 1-9.
7. Petrosillo N, Chinello P, Proietti MF et al. Combined colistin and rifampin therapy for carbapenem-resistant Acinetobacter baumannii infections: Clinical outcome and adverse events. Clin Microbiol Infect 2005; 11: 682-683.
8. Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 2946-2950.
9. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41: 149-158.
10. Bliziotis IA, Ntziora F, Lawrence KR, Falagas ME. Rifampin as adjuvant treatment of Gram-positive bacterial infections: A systematic review of comparative clinical trials. Eur J Clin Microbiol Infect Dis 2007; 26: 849-856.
11. Falagas ME, Matthaiou DK, Bliziotis IAJ. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: A meta-analysis of comparative trials. J Antimicrob Chemother 2006; 57: 639-647.
12. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomised trials. BMJ 2004; 328: 668.
13. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: Systematic review and meta-analysis. BMJ 2003; 326: 1111.
14. Hawley JS, Murray CK, Jorgensen JH. Development of colistin-dependent Acinetobacter baumanni - calcoaceticus complex. Antimicrob Agents Chemother 2007; 51: 4529-4530.
15. Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin.B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 270-271.
16. Hogg GM, Barra JG, Webb CH. In-vitro activity of the combination of colistin and rifampin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 1998; 41: 494-495.
17. Rynn C, Wootton M, Bowker KE, Alan Holt, Reeves DS. In.vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999; 5: 32-36.
18. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampicin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001; 40: 117-120.
19. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2002; 44: 259-263.
20. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In.vitro double and triple synergistic activities of polymyxin.B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004; 48: 753-757.
21. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In.vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003; 15: 235-238.
22. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotscahfer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in.vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 905-909.
23. Tascini C, Gemignani G, Ferranti S et.al. Microbiological activity and clinical efficacy and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 2004; 16: 282-287.
24. Hill D, Rose B, Pajkos A et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microb 2005; 43: 5085-5090.
25. Giacometti A, Cirioni O, Kamysz W et al. In.vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. Antimicrob Agents Chemother 2005; 49: 1249-1252.
26. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In.vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27: 224-228.
27. Cirioni O, Ghiselli R, Silvestri C et al. Efficacy of tachyplesin. III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. Antimicrob Agents Chemother 2007; 51: 2005-2010.
28. Song JY, Kee SY, Hwang IS et al. In.vitro activities of carbapenem/ sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 60: 317-322.
29. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: Promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007; 45: 594-598.
30. Tan TY, Ng LS, Tan E, Huang G. In.vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 60: 421-423.
31. Saslaw S, Carlisle HN, Moheimani M. Comparison of colistin-carbenicillin, colistin, and carbenicillin in Pseudomonas sepsis in monkeys. Antimicrob Agents Chemother 1973; 3: 118-124.
32. Giacometti A, Cirioni O, Ghiselli R et al. Antiendotoxin activity of antimicrobial peptides and glycopeptides. J Chemother 2003; 15: 129-133.
33. Montero A, Ariza J, Corbella X et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54: 1085-1091.
34. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: The significance of co-administration of rifampicin. Int J Antimicrob Agents 2007; 29: 51-55.
35. Cirioni O, Ghiselli R, Orlando F et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit Care Med 2007; 35: 1717-1723.
36. Tascini C, Gemignani G, Palumbo F et al. Clinical and microbiological effectiveness of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 2006; 18: 648-651.
37. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant gram-negative bacterial infections. Clin Microbiol Infect 2006; 12: 1227-1230.
38. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: 154-160.
39. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52: 987-993.
40. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-3146.
41. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-121.
42. Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274-278.
43. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003; 7: 78-83.
44. Kallel H, Bahloul M, Hergafi L et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006; 28: 366-369.
45. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 2002; 35: 901-902.
46. Reina R, Estenssoro E, Saenz G et al. Safety and effectiveness of colistin in Acinetobacter and Pseudomonas infections: A prospective cohort study. Intensive Care Med 2005; 31: 1058-1065.
47. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36: 1111-1118.
48. Hachem RY, Chemaly RF, Ahmar CA et al. Colistin is effective in the treatment of multidrug-resistant Pseudomonas aeruginosa infections in cancer patients. Antimicrob Agents Chemother 2007; 51: 905-911.
49. Pournaras S, Ikonomidis A, Markogiannakis A, Maniatis AN, Tsakris A. Heteroresistance to carbapenems in Acinetobacter baumannii. J Antimicrob Chemother 2005; 55: 1055-1056.
50. Rinder H. Hetero-resistance: An under-recognised confounder in diagnosis and therapy? J Med Microbiol 2001; 50: 1018-1020.